Danny Truong, DO
Payments from drug & device makers
What this record shows
The money is spread across several categories — food and beverage (45.4%), travel and lodging and consulting fees — rather than concentrated in one kind of arrangement. It is spread thinly across 17 manufacturers, the largest accounting for just 21.0%.
Across 169 payments — averaging $72.62 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Medtronic$3K
- Boston Scientific$3K
- Acadia Pharmaceuticals Inc$2K
- AbbVie$2K
- Abbott$1K
- Amneal Pharmaceuticals LLC$881
- plus $2K from 11 others
What the payments were for
- Consulting fees$3,01325%
- Travel & lodging$3,53429%
- Food & beverage$5,56845%
- Education$1571%
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Medtronic | 35 | $2,582 |
| Boston Scientific | 11 | $2,511 |
| Acadia Pharmaceuticals Inc | 18 | $1,849 |
| AbbVie | 42 | $1,707 |
| Abbott | 18 | $1,171 |
| Amneal Pharmaceuticals LLC | 9 | $881 |
| Amgen | 4 | $376 |
| Teva Pharmaceuticals USA, Inc. | 4 | $242 |
| Sanofi | 2 | $215 |
| Merz Pharmaceuticals, LLC | 9 | $169 |
| AstraZeneca | 2 | $145 |
| Kyowa Kirin, Inc. | 4 | $91 |
| Pfizer | 2 | $84 |
| Cala Health, Inc. | 2 | $78 |
| UCB, Inc. | 3 | $74 |
| Avion Pharmaceuticals | 3 | $61 |
| Revance Therapeutics, Inc. | 1 | $40 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
How this compares
$12,272 in reported general payments places this provider in the 75th percentile of 145 neurology providers in Nevada.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| RytaryCarbidopa/Levodopa | 54 | $102,885 |
| IngrezzaValbenazine Tosylate | 11 | $88,721 |
| NuplazidPimavanserin Tartrate | 14 | $71,670 |
| GocovriAmantadine Hcl | 15 | $54,977 |
| NourianzIstradefylline | 13 | $41,151 |
| CrexontCarbidopa/Levodopa | 17 | $18,435 |
| Carbidopa-LevodopaCarbidopa/Levodopa | 322 | $18,282 |
| Entacapone | 39 | $12,487 |
| Rasagiline Mesylate | 24 | $5,211 |
| RivastigmineRivastigmine Tartrate | 64 | $4,489 |
| Rivastigmine | 13 | $4,196 |
| Carbidopa-Levodopa ErCarbidopa/Levodopa | 77 | $3,899 |
| Propranolol Hcl ErPropranolol Hcl | 46 | $2,445 |
| AmantadineAmantadine Hcl | 21 | $1,875 |
| Topiramate | 62 | $1,874 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| Amneal Pharmaceuticals LLCRytary, Crexont | $881 | $121,32071 claims |
| Acadia Pharmaceuticals IncNuplazid | $1,849 | $71,67014 claims |
| Kyowa Kirin, Inc.Nourianz | $91 | $41,15113 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 75th percentile of 145 neurology providers in Nevada.
Other neurology in Reno
- Melissa BlochReno$883K
- Burton TabaacReno$287K
- G BigleyReno$133K
- Lee GerwitzReno$88K
- Verena SamaraReno$64K
- Frank QuaglieriReno$21K
- Timothy LouieReno$15K
- Yen-Yi PengReno$14K
- Rolando AniaReno$9K
- Byung Chan AhnReno$5K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.